Clinical Trial Update: Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pembrolizumab in patients with diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma who failed or relapsed af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: CD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-12